Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma.

Guinan EC, Kalish LA, Berry WS, McDaniel S, Lehmann LE, Diller LR.

Pediatr Transplant. 2006 Sep;10(6):669-76.

PMID:
16911489
3.
4.
6.

Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).

Bernbeck B, Bahci S, Meisel R, Troeger A, Schönberger S, Laws HJ, Kramm C, Wessalowski R, Koscielniak E, Dilloo D, Göbel U.

Klin Padiatr. 2007 Nov-Dec;219(6):318-22.

PMID:
18050041
7.

Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.

Puig N, de la Rubia J, Remigia MJ, Jarque I, Martín G, Cupelli L, Sanz GF, Lorenzo I, Sanz J, Martínez JA, Jiménez C, Sanz MA.

Leuk Lymphoma. 2006 Aug;47(8):1488-94.

PMID:
16966258
8.

Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.

Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T.

Bone Marrow Transplant. 2008 Apr;41(7):613-9. Epub 2007 Dec 10.

PMID:
18071290
9.

Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.

Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1343-9.

10.

Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.

Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM.

Br J Haematol. 2008 Oct;143(2):268-73. doi: 10.1111/j.1365-2141.2008.07342.x. Epub 2008 Aug 10.

PMID:
18699848
11.

Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.

Wong R, Rondon G, Saliba RM, Shannon VR, Giralt SA, Champlin RE, Ueno NT.

Bone Marrow Transplant. 2003 Jun;31(12):1157-63.

PMID:
12796796
12.

Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient.

Lones MA, Kirov I, Said JW, Shintaku IP, Neudorf S.

Bone Marrow Transplant. 2000 Nov;26(9):1021-4. Review.

13.

Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma.

Parsons SK, Neault MW, Lehmann LE, Brennan LL, Eickhoff CE, Kretschmar CS, Diller LR.

Bone Marrow Transplant. 1998 Oct;22(7):669-74.

14.

Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.

Avramova B, Jordanova M, Michailov G, Konstantinov D, Christosova I, Bobev D.

J BUON. 2006 Oct-Dec;11(4):433-8.

PMID:
17309174
16.

A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.

Yoshimi A, Nannya Y, Sakata-Yanagimoto M, Oshima K, Takahashi T, Kanda Y, Motokura T, Chiba S, Kurokawa M.

Am J Hematol. 2008 Aug;83(8):635-9. doi: 10.1002/ajh.21208.

17.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Haematologica. 2007 May;92(5):627-34.

18.

Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma.

Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, Shin HJ, Jung JS, Kim WS, Kim DH, Suh C, Kim SJ, Eom HS, Bae SH.

Bone Marrow Transplant. 2007 Nov;40(10):919-24. Epub 2007 Sep 10.

PMID:
17846602
20.

BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.

Talamo G, Claxton DF, Dougherty DW, Ehmann CW, Sivik J, Drabick JJ, Rybka W.

Bone Marrow Transplant. 2009 Aug;44(3):157-61. doi: 10.1038/bmt.2008.446. Epub 2009 Feb 9.

PMID:
19204716

Supplemental Content

Support Center